Amico Lab, Inc.: FDA filings under this applicant name
FDA lists 32 510(k) clearances under the applicant name “Amico Lab, Inc.” (first 1982, latest 1985), across 12 product codes in 3 review panels. Median 510(k) review time under this name: 75 days. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 0 | — |
| 2013 | 0 | — |
| 2014 | 0 | — |
| 2015 | 0 | — |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 0 | — |
| 2019 | 0 | — |
| 2020 | 0 | — |
| 2021 | 0 | — |
| 2022 | 0 | — |
| 2023 | 0 | — |
| 2024 | 0 | — |
| 2025 | 0 | — |
| 2026 | 0 | — |
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| DFH | Kappa, Antigen, Antiserum, Control | 14 | 14 |
| DHN | Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control | 2 | 2 |
| GNH | Antigen, Fluorescent Antibody Test, Schistosoma Mansoni | 2 | 2 |
| GNP | Antiserum, Cf, Epstein-Barr Virus | 2 | 2 |
| GQI | Antiserum, Cf, Cytomegalovirus | 2 | 2 |
| GQO | Antisera, Cf, Herpesvirus Hominis 1,2 | 2 | 2 |
| LJM | Antinuclear Antibody (Enzyme-Labeled), Antigen, Controls | 2 | 2 |
| LJP | Antiserum, Fluorescent, Chlamydia Trachomatis | 2 | 2 |
| GLZ | Antigens, If, Toxoplasma Gondii | 1 | 1 |
| IOR | Wheelchair, Mechanical | 1 | 1 |
Plus 2 more product codes.
Review panels
- Immunology (18)
- Microbiology (13)
- Physical Medicine (1)
Most recent Amico Lab, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K842662 | ANTI-EPSTEIN-BARR VIRUS KIT | GNP | 1985-12-12 | 520 |
| K842663 | ANTI-HERPES SIMPLEX VIRUS TYPE 1 OR 2 | GQO | 1985-12-06 | 514 |
| K842661 | ANTI-CYTOMEGALOVIRUS KIT | GQI | 1985-12-06 | 514 |
| K842531 | AMIZYME-HSV TYPES 1 & 2 TEST KITS | GQO | 1985-12-06 | 526 |
| K842530 | AMIZYME-EBV TEST KIT | GNP | 1985-12-06 | 526 |
| K842529 | AMIZYME-CMV KIT | GQI | 1985-12-06 | 526 |
| K842660 | ANTI-SCHISTOSOMA SPECIES KIT | GNH | 1984-10-30 | 112 |
| K842658 | ANTI-CHLAMYDIA TRACHOMATIS KIT | LJP | 1984-10-01 | 83 |
| K842525 | AMIZYME-C TRACHOMATIS TEST KIT | LJP | 1984-10-01 | 95 |
| K842533 | AMIZYME-ANDNA TEST KIT | LJM | 1984-09-20 | 84 |
22 earlier clearances. See the full list in Caduvo.
Recalls
FDA recall records list no recalls under a recalling firm named Amico Lab, Inc..
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Amico Diagnostic Incorporated (1 510(k)s)
- Amico Laboratories, Inc. (1 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Amico Lab, Inc.?
FDA lists 32 510(k) clearances under the applicant name “Amico Lab, Inc.” (first 1982, latest 1985), across 12 product codes in 3 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Amico Lab, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Amico Lab, Inc. is 75 days.
Which FDA product codes appear under Amico Lab, Inc.?
The most frequent FDA product codes under this applicant name are DFH (Kappa, Antigen, Antiserum, Control, 14); DHN (Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control, 2); GNH (Antigen, Fluorescent Antibody Test, Schistosoma Mansoni, 2).
Next steps
- See all 32 Amico Lab, Inc. clearances with predicates and recalls
- Run predicate analysis for product code DFH, Amico Lab, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant name shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.